BioTAK Score Uses Sex and Two Novel Biomarkers to Flag Takotsubo Before Catheterization

An international consortium led by researchers at Zurich, Oxford, and Greifswald developed and validated the BioTAK score from the InterTAK Registry. The model combines sex with circulating proteins reflecting neuropeptide activation and atherosclerotic plaque stability. In the validation set the score reached predefined thresholds that identified Takotsubo cases with high accuracy while also revealing a brain-heart axis signature distinct from plaque rupture.

The study design was prospective observational with a separate validation cohort; no randomization or clinical-outcome endpoints were assessed. Relative to prior single-marker attempts, BioTAK improved discrimination by integrating stress-response and vascular-stability pathways, yet absolute event rates in the source populations remain low and external cohorts outside Europe are absent.

If adopted, the score could triage selected postmenopausal women away from immediate catheterization when pretest probability is low, but guidelines will require randomized trials measuring catheterization rates, length of stay, and missed myocardial infarction before routine use. Ongoing registry follow-up will test temporal stability of the biomarker thresholds.